Assessment of serum levels of anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: A cross-sectional study in a Brazilian cohort.
anti-cyclic citrullinated peptides
autoantibodies
psoriasis
Journal
Biomedical reports
ISSN: 2049-9434
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
12
03
2020
accepted:
10
07
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
ppublish
Résumé
Presence of the anti-cyclic citrullinated peptide (CCP) antibody is considered a hallmark of rheumatoid arthritis, and may be found in patients with other rheumatic diseases, including psoriatic arthritis (PsA). The aim of the present study was to determine whether the anti-CCP antibody was present in patients with psoriasis with and without arthritis. and to determine whether its presence was associated with clinical, serological and treatment data in patients with PsA. The present study was a cross-sectional study, which included 91 patients with psoriasis (41 with arthritis and 48 without arthritis) as well as an age and sex matched control group consisting of 100 healthy individuals. Presence of the anti-CCP antibody was determined using commercially available ELISA kits. Data on clinical, serological and treatment characteristics was obtained from reviewing each patient's medical history. The quality of life and articular inflammatory activity were assessed using the Short Form Health Survey-12 questionnaire. Skin disease was evaluated using the Psoriasis Area Severity Index and body surface area. In the control group, 1% of individuals were positive for the anti-CCP antibody, whereas 17.5% of the psoriasis patients were positive (P<0.001). In the patients with PsA, 20.9% were positive for the antibody, and in patients with psoriasis without joint disease, 14.5% were positive (P=0.58). Patients with polyarticular forms of PsA were more likely to be anti-CCP positive compared with patients with skin disease without arthritis (P=0.009). In the group of patients with PsA, those who were anti-CCP positive were more likely to suffer from polyarticular forms of arthritis, but no differences were found in the quality of life, joint disease activity, degree of skin involvement and treatment requirements (all P>0.05). In conclusion, 17.5% of patients with psoriasis and 20.9% of patients with PsA were positive for anti-CCP antibodies. Polyarticular arthritis was more common in the anti-CCP positive patients compared with the anti-CCP negative patients.
Identifiants
pubmed: 32843964
doi: 10.3892/br.2020.1343
pii: BR-0-0-01343
pmc: PMC7441599
doi:
Types de publication
Journal Article
Langues
eng
Pagination
36Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
J Dermatol. 2010 May;37(5):426-30
pubmed: 20536647
Ann Rheum Dis. 2006 Mar;65(3):398-400
pubmed: 16096328
Ann Rheum Dis. 2009 Jan;68(1):18-24
pubmed: 18625618
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
Rheumatol Int. 2014 Feb;34(2):227-34
pubmed: 24114527
Acta Reumatol Port. 2013 Jul-Sep;38(3):172-8
pubmed: 24149013
Rheumatology (Oxford). 2005 Aug;44(8):1056-60
pubmed: 15901902
Mymensingh Med J. 2014 Jul;23(3):609-13
pubmed: 25178623
J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:17-26
pubmed: 24985559
Actas Dermosifiliogr. 2015 Jul-Aug;106(6):452-7
pubmed: 26026773
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Br J Dermatol. 2005 May;152(5):861-7
pubmed: 15888138
J Clin Rheumatol. 2006 Oct;12(5):226-9
pubmed: 17023808
Rheumatol Int. 2014 Sep;34(9):1211-6
pubmed: 24515446
Rheumatology (Oxford). 2016 Oct;55(10):1791-5
pubmed: 27330166
Clin Rheumatol. 2007 Jan;26(1):17-23
pubmed: 16538391
J Bras Pneumol. 2007 Jul-Aug;33(4):414-22
pubmed: 17982533
Clin Lab Sci. 2008 Winter;21(1):15-8
pubmed: 18335856
J Dermatol. 2010 Apr;37(4):339-45
pubmed: 20507403
Cent Eur J Immunol. 2017;42(4):390-398
pubmed: 29472818
J Med Life. 2013;6(4):376-82
pubmed: 24701255
Indian J Dermatol. 2016 Sep-Oct;61(5):510-4
pubmed: 27688439
Eur J Rheumatol. 2014 Jun;1(2):67-71
pubmed: 27708878